Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | aldo-keto reductase | 0.0356 | 1 | 1 |
Trypanosoma brucei | prostaglandin f synthase | 0.0356 | 1 | 1 |
Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0356 | 1 | 1 |
Toxoplasma gondii | oxidoreductase, aldo/keto reductase family protein | 0.0103 | 0.2403 | 0.2278 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Plasmodium falciparum | aldehyde reductase, putative | 0.0103 | 0.2403 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0664 | 0.051 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Toxoplasma gondii | aldo/keto reductase family oxidoreductase | 0.0103 | 0.2403 | 0.2278 |
Toxoplasma gondii | aldo-keto reductase | 0.0103 | 0.2403 | 0.2278 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0118 | 0.2851 | 0.2733 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Echinococcus granulosus | snurportin 1 | 0.0304 | 0.8446 | 0.8421 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0103 | 0.2403 | 0.2403 |
Echinococcus multilocularis | aldehyde reductase | 0.0253 | 0.6902 | 0.6851 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0356 | 1 | 1 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Trypanosoma cruzi | aldo/keto reductase, putative | 0.0103 | 0.2403 | 0.2403 |
Entamoeba histolytica | alcohol dehydrogenase, putative | 0.0103 | 0.2403 | 0.2403 |
Loa Loa (eye worm) | oxidoreductase | 0.0356 | 1 | 1 |
Schistosoma mansoni | pol-related | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0356 | 1 | 1 |
Brugia malayi | RNA, U transporter 1 | 0.0081 | 0.1741 | 0.1605 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0664 | 0.051 |
Echinococcus granulosus | aldo keto reductase | 0.0356 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0304 | 0.8446 | 0.8421 |
Entamoeba histolytica | alcohol dehydrogenase, putative | 0.0103 | 0.2403 | 0.2403 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Giardia lamblia | Aldose reductase | 0.0356 | 1 | 0.5 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Leishmania major | prostaglandin f synthase, putative | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase | 0.0356 | 1 | 1 |
Plasmodium vivax | oxidoreductase, aldo/keto reductase domain containing protein | 0.0103 | 0.2403 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Leishmania major | aldo-keto reductase-like protein | 0.0356 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0664 | 0.051 |
Brugia malayi | glutamate-cysteine ligase modifier subunit | 0.0103 | 0.2403 | 0.2278 |
Loa Loa (eye worm) | glutamate-cysteine ligase modifier subunit | 0.0103 | 0.2403 | 0.2278 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0356 | 1 | 1 |
Echinococcus multilocularis | voltage gated potassium channel subunit | 0.0103 | 0.2403 | 0.2278 |
Mycobacterium leprae | PROBABLE OXIDOREDUCTASE | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldehyde reductase | 0.0253 | 0.6902 | 0.6851 |
Plasmodium vivax | aldehyde reductase, putative | 0.0103 | 0.2403 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.0664 | 0.051 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0045 | 0.0664 | 0.051 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Plasmodium falciparum | aldo-keto reductase, putative | 0.0103 | 0.2403 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Trypanosoma brucei | aldo/keto reductase, putative | 0.0103 | 0.2403 | 0.2278 |
Giardia lamblia | Aldose reductase | 0.0356 | 1 | 0.5 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Entamoeba histolytica | aldose reductase, putative | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0118 | 0.2851 | 0.2733 |
Leishmania major | prostaglandin f2-alpha synthase/D-arabinose dehydrogenase | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Toxoplasma gondii | aldose reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0103 | 0.2403 | 0.2403 |
Schistosoma mansoni | potassium channel beta | 0.0103 | 0.2403 | 0.2278 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0103 | 0.2403 | 0.2403 |
Echinococcus multilocularis | aldo keto reductase | 0.0356 | 1 | 1 |
Leishmania major | aldo/keto reductase, putative,aldo/keto reductase family-like protein | 0.0103 | 0.2403 | 0.2403 |
Echinococcus granulosus | aldo keto reductase | 0.0356 | 1 | 1 |
Echinococcus granulosus | hypothetical protein | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0253 | 0.6902 | 0.5922 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0118 | 0.2851 | 0.2733 |
Trichomonas vaginalis | aldo/keto reductase, putative | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo/keto reductase, putative | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | alcohol dehydrogenase, putative | 0.0103 | 0.2403 | 0.2403 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase | 0.0356 | 1 | 1 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1, member B4 | 0.0103 | 0.2403 | 0.2278 |
Echinococcus granulosus | voltage gated potassium channel subunit | 0.0103 | 0.2403 | 0.2278 |
Trypanosoma brucei | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo/keto reductase, putative | 0.0356 | 1 | 1 |
Leishmania major | aldehyde reductase, putative,oxidoreductase, putative | 0.0356 | 1 | 1 |
Trypanosoma cruzi | aldo/keto reductase, putative | 0.0356 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.0664 | 0.051 |
Loa Loa (eye worm) | nucleolar RNA-associated protein alpha | 0.0304 | 0.8446 | 0.8421 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0103 | 0.2403 | 0.2403 |
Echinococcus multilocularis | aldo keto reductase | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Entamoeba histolytica | aldose reductase, putative | 0.0356 | 1 | 1 |
Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Echinococcus multilocularis | snurportin 1 | 0.0304 | 0.8446 | 0.8421 |
Schistosoma mansoni | aldo-keto reductase | 0.0356 | 1 | 1 |
Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0356 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.0664 | 0.051 |
Mycobacterium ulcerans | oxidoreductase | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.0664 | 0.051 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 0.0664 | 0.051 |
Loa Loa (eye worm) | hypothetical protein | 0.0356 | 1 | 1 |
Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Entamoeba histolytica | aldose reductase, putative | 0.0356 | 1 | 1 |
Brugia malayi | NADH-dependent xylose reductase | 0.0103 | 0.2403 | 0.2278 |
Trypanosoma cruzi | aldo-keto reductase | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0356 | 1 | 1 |
Trichomonas vaginalis | aldo-keto reductase, putative | 0.0356 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | < 0.3 ug ml-1 | In vitro inhibition of KB cell growth. | ChEMBL. | 3806570 |
IC50 (functional) | < 0.3 ug ml-1 | Antitumor activity was determined by the ability to inhibit KB cell growth | ChEMBL. | 3116257 |
IC50 (functional) | = 0.5 ug ml-1 | In vitro inhibition of KB cell growth | ChEMBL. | 3599030 |
IC50 (functional) | = 0.3 uM | Inhibit growth of FM3A cells by 50% | ChEMBL. | 1732542 |
IC50 (functional) | = 0.4 uM | Inhibit growth of FM3A cells by 50% | ChEMBL. | 1732542 |
IC50 (functional) | = 0.4 uM | Inhibit growth of FM3A cells by 50% | ChEMBL. | 1732542 |
IC50 (functional) | = 1.1 uM | Inhibit growth of KB cells by 50% | ChEMBL. | 1732542 |
IC50 (functional) | > 199 uM | Inhibit growth of FM3A cells by 50% | ChEMBL. | 1732542 |
ID50 (functional) | = 1.1 nM ml-1 | In vitro inhibitory activity against growth of KB cells derived from human epidermoid carcinoma of the mouth | ChEMBL. | 6502608 |
ID50 (functional) | = 1.1 nM ml-1 | In vitro inhibitory activity against growth of KB cells | ChEMBL. | 4020825 |
ID50 (functional) | = 1.1 nM ml-1 | In vitro inhibitory activity against growth of KB cells derived from human epidermoid carcinoma of the mouth | ChEMBL. | 6502608 |
ID50 (functional) | = 0.5 ug ml-1 | In vitro inhibitory activity against growth of KB cells derived from human epidermoid carcinoma of the mouth | ChEMBL. | 6502608 |
ID50 (functional) | = 0.5 ug ml-1 | In vitro inhibitory activity against growth of KB cells | ChEMBL. | 4020825 |
ID50 (functional) | = 0.5 ug ml-1 | In vitro inhibitory activity against growth of KB cells derived from human epidermoid carcinoma of the mouth | ChEMBL. | 6502608 |
Imbalance (functional) | NT 0 | Ability to induce dNTP pool imbalance at 41 microM dose was tested; significant imbalance in the intracellular dNTP pool in FM3A cells | ChEMBL. | 1732542 |
T/C (functional) | NA 0 % | Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 200 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 103 % | Antitumor activity in P388 innoculated mice following 10 mg/kg i.p. administration. | ChEMBL. | 3806570 |
T/C (functional) | = 103 % | Antitumor activity in P388 innoculated mice following 10 mg/kg i.p. administration. | ChEMBL. | 3806570 |
T/C (functional) | = 127 % | Compound was tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 0.6 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 127 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 0.6 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 127 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 0.6 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 127 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 0.6 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 127 % | In vivo antitumor activity against leukemia P388 in mice at 0.6 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 127 % | Compound was tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 0.6 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 127 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 0.6 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 127 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 0.6 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 127 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 0.6 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 127 % | In vivo antitumor activity against leukemia P388 in mice at 0.6 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 134 % | Antitumor activity against leukemia P388 cell line in mice was determined at 2.5 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 134 % | Compound was tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 2.5 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 134 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 2.5 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 134 % | Antitumor activity of the compound against P388, was determined by injecting intraperitoneally in mice, at a dose of 2.5 mg/kg | ChEMBL. | 3806570 |
T/C (functional) | = 134 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 2.5 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 134 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 2.5 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 134 % | In vivo antitumor activity against leukemia P388 in mice at 2.5 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 134 % | Antitumor activity against leukemia P388 cell line in mice was determined at 2.5 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 134 % | Compound was tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 2.5 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 134 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 2.5 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 134 % | Antitumor activity of the compound against P388, was determined by injecting intraperitoneally in mice, at a dose of 2.5 mg/kg | ChEMBL. | 3806570 |
T/C (functional) | = 134 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 2.5 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 134 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 2.5 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 134 % | In vivo antitumor activity against leukemia P388 in mice at 2.5 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 169 % | Compound was tested in vivo for the antitumor activity against P388 in mice after intraperitoneal administration of 0.6 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 170 % | Antitumor activity against leukemia P388 cell line in mice was determined at 10 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 170 % | Antitumor activity of the compound against P388, was determined by injecting intraperitoneally in mice, at a dose of 10 mg/kg | ChEMBL. | 3806570 |
T/C (functional) | = 170 % | Antitumor activity against leukemia P388 cell line in mice was determined at 10 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 170 % | Antitumor activity of the compound against P388, was determined by injecting intraperitoneally in mice, at a dose of 10 mg/kg | ChEMBL. | 3806570 |
T/C (functional) | = 173 % | Antitumor activity against leukemia P388 cell line in mice was determined at 5 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 173 % | Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 5 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 173 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 5 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 173 % | Antitumor activity in P388 innoculated mice following 5 mg/kg i.p. administration. | ChEMBL. | 3806570 |
T/C (functional) | = 173 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 5 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 173 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 5 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 173 % | In vivo antitumor activity against leukemia P388 in mice at 5 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 173 % | Antitumor activity against leukemia P388 cell line in mice was determined at 5 mg/kg intraperitoneal dose | ChEMBL. | 3116257 |
T/C (functional) | = 173 % | Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 5 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
T/C (functional) | = 173 % | In vivo antitumor activity of the compound was measured in mice (P388 leukemia) at dose 5 mg/kg after intraperitoneal administration | ChEMBL. | 6502608 |
T/C (functional) | = 173 % | Antitumor activity in P388 innoculated mice following 5 mg/kg i.p. administration. | ChEMBL. | 3806570 |
T/C (functional) | = 173 % | Compound was evaluated for activity against P388 leukemia, at an intraperitoneal dose of 5 mg/kg | ChEMBL. | 3806588 |
T/C (functional) | = 173 % | In vivo antitumor activity of the compound against leukemia P388 in mice after intraperitoneal administration of the compound at a dose of 5 mg/kg once a day for 1 and 5 days | ChEMBL. | 4020825 |
T/C (functional) | = 173 % | In vivo antitumor activity against leukemia P388 in mice at 5 mg/kg dosage administered intraperitoneally once a day for 1 and 5 days | ChEMBL. | 3599030 |
T/C (functional) | = 180 % | Compound was tested in vivo for the antitumor activity against P388 leukemia cells in mice after intraperitoneal administration of 5 mg/kg dose; T/C= treated/control | ChEMBL. | 1732542 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 1732542 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
7 literature references were collected for this gene.